Treatment of asthma with anti-immunoglobulin E monoclonal antibody

Allergy and Asthma Proceedings

Volumn 27, Issue 2 SUPPL. 1, 2006, Pages

  Liu, Andrew H ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY; OMALIZUMAB;

ADOLESCENT; ADULT; AGE; ASTHMA; CHILD; COMPARATIVE STUDY; CONFERENCE PAPER; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; LUNG FUNCTION TEST; MALE; MAXIMUM TOLERATED DOSE; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MAXIMUM TOLERATED DOSE; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33646482620     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Nelson HS, Szefler SJ, Jacobs J, et al. The relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program. J Allergy Clin Immunol 104:775-785, 1999.
2. Guilbert TW, Morgan WJ, Zeiger RS, et al. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. J Allergy Clin Immunol 114:1282-1287, 2004.
3. Illi S, von Mutius E, Lau S, et al. The pattern of atopic sensitization is associated with the development of asthma in childhood. J Allergy Clin Immunol 108:709-714, 2001.
4. Perry T, Matsui E, Merriman B, et al. The prevalence of rat allergen in inner-city homes and its relationship to sensitization and asthma morbidity. J Allergy Clin Immunol 112:346-352, 2003.
5. Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 336:1356-1363, 1997.
6. Platts-Mills TAE, Tovey ER, Mitchell EB, et al. Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet 2:675-678, 1982.
7. Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 351:1068-1080, 2004.
8. Shirai T, Matsui T, Suzuki K, and Chida K. Effect of pet removal on pet allergic asthma. Chest 127:1565-1571, 2005.
9. Chang TW. Developing antibodies for targeting IgE and mIgE. Allergy Asthma Proc 27:S7-S14, 2006.
10. Soresi S, and Togias A. Mechanisms of action of anti-IgE therapy. Allergy Asthma Proc 27:S15-S23, 2006.
11. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184-190, 2001.
12. Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 91:154-159, 2003.
13. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254-261, 2001.
14. Holgate S, Chuchalin AG, Herbert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34:632-638, 2004.
15. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108:E36, 2001.
16. Berger W, Gupta N, McAlary M, et al. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 91:182-188, 2003.
17. Deniz YM, and Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 29:273-290, 2005.
18. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patient with severe persistent asthma. Allergy 60:302-308, 2005.
19. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patient with allergic asthma. Chest 125:1378-1386, 2004.
20. Szefler SJ, Martin AJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109:410-418, 2002.
21. Spahn JD, Leung DYM, Surs W, et al. Reduced glucocorticoid binding affinity in asthma ir related to ongoing allergic inflammation. Am J Respir Crit Care Med 151:1709-1714, 1995.
22. Nimmagadda SR, Szefler SJ, Spahn JD, et al. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. Am J Respir Crit Care Med 155:87-93, 1997.